| | Survival outcome | Study . | Patient . | Model | HR (95% CI) | value | Heterogeneity (, ) | Conclusion |
| miR-210 total | RFS/DFS | 7 | 699 | Random | 2.47 [1.36, 4.46] | 0.003 | 62%, 0.01 | Positive | OS | 3 | 314 | Fixed | 3.44 [1.95, 6.06] | <0.0001 | 0%, 0.96 | Positive | MFS/DRFS | 3 | 624 | Fixed | 2.85 [1.76, 4.62] | <0.0001 | 0%, 0.96 | Positive | DSS | 2 | 134 | Fixed | 2.68 [1.58, 4.54] | 0.0003 | 0%, 0.67 | Positive | miR-210 breast cancer | RFS/DFS | 4 | 542 | Fixed | 3.36 [2.30, 4.93] | <0.00001 | 0%, 0.86 | Positive | OS | 2 | 268 | Fixed | 3.29 [1.65, 6.58] | 0.0008 | 0%, 0.84 | Positive | MFS/DRFS | 3 | 624 | Fixed | 2.85 [1.76, 4.62] | <0.0001 | 0%, 0.96 | Positive | miR-210 head and neck cancer | RFS/DFS | 1 | 46 | Fixed |
4.89 [1.71, 13.93] | 0.003 | — | Positive | OS | 1 | 46 | Fixed | 3.77 [1.41, 10.03] | 0.008 | — | Positive | miR-210 soft-tissue sarcoma | DSS | 1 | 78 | Fixed | 3.19 [1.22, 8.33] | 0.02 | — | Positive | miR-210 pancreatic cancer | DSS | 1 | 56 | Fixed | 2.48 [1.32, 4.68] | 0.005 | — | Positive | miR-210 renal cell carcinoma | RFS/DFS | 2 | 111 | Fixed | 0.50 [0.19, 1.30] | 0.16 | 0%, 0.45 | Negative |
|
|